Pacira Pharmaceuticals Company Insiders
| PCRX Stock | USD 25.90 0.91 3.39% |
Pacira Pharmaceuticals' insiders are aggressively selling. The analysis of insiders' sentiment of trading Pacira Pharmaceuticals stock suggests that vertually all insiders are panicking at this time. Pacira Pharmaceuticals employs about 711 people. The company is managed by 33 executives with a total tenure of roughly 199 years, averaging almost 6.0 years of service per executive, having 21.55 employees per reported executive.
| David Stack Chairman Chairman and CEO |
| James Jones President Senior Vice President Chief Medical Officer |
Pacira Pharmaceuticals' Insider Buying Vs Selling
0
Selling | Buying |
Latest Trades
| 2024-03-08 | Gary W Pace | Disposed 90000 @ 30.6 | View | ||
| 2024-03-06 | Gary W Pace | Disposed 1066 @ 29.67 | View | ||
| 2023-08-02 | Roy Winston | Disposed 509 @ 34.88 | View | ||
| 2023-07-05 | Lauren Bullaro Riker | Disposed 643 @ 38.91 | View | ||
| 2023-06-14 | Lauren Bullaro Riker | Disposed 6366 @ 38.42 | View | ||
| 2023-06-08 | Mark A Kronenfeld | Disposed 15000 @ 37.04 | View | ||
| 2023-06-07 | Daryl Gaugler | Disposed 1047 @ 37.87 | View | ||
| 2023-06-06 | Lauren Bullaro Riker | Disposed 591 @ 38.99 | View | ||
| 2023-06-05 | Paul J Hastings | Disposed 580 @ 38.34 | View | ||
| 2023-05-31 | Daryl Gaugler | Disposed 2500 @ 39.08 | View | ||
| 2023-05-11 | Gary W Pace | Disposed 5015 @ 41.78 | View |
Monitoring Pacira Pharmaceuticals' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Pacira |
Pacira Pharmaceuticals' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Pacira Pharmaceuticals' future performance. Based on our forecasts, it is anticipated that Pacira will maintain a workforce of slightly above 710 employees by May 2024.Pacira Pharmaceuticals' latest congressional trading
Congressional trading in companies like Pacira Pharmaceuticals, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Pacira Pharmaceuticals by those in governmental positions are based on the same information available to the general public.
| 2021-05-06 | Representative Tom Malinowski | Acquired Under $15K | Verify |
Pacira Pharmaceuticals Management Team Effectiveness
The company has return on total asset (ROA) of 0.0335 % which means that it generated a profit of $0.0335 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.051 %, meaning that it created $0.051 on every $100 dollars invested by stockholders. Pacira Pharmaceuticals' management efficiency ratios could be used to measure how well Pacira Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to 0.05 in 2024. Return On Capital Employed is likely to rise to 0.06 in 2024. At this time, Pacira Pharmaceuticals' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 1.1 B in 2024, whereas Other Assets are likely to drop 0.95 in 2024.Net Income Applicable To Common Shares is likely to rise to about 19.2 M in 2024, whereas Common Stock Shares Outstanding is likely to drop slightly above 35.9 M in 2024.
Pacira Pharmaceuticals Workforce Comparison
Pacira Pharmaceuticals is regarded fifth in number of employees category among related companies. The total workforce of Health Care industry is at this time estimated at about 35,080. Pacira Pharmaceuticals holds roughly 711 in number of employees claiming about 2.03% of equities under Health Care industry.
The company has Profit Margin (PM) of 0.06 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.19 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.19. Pacira Pharmaceuticals Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Pacira Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Pacira Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Pacira Pharmaceuticals insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2024-03-01 | 1.5 | 6 | 4 | 874,432 | 119,482 |
| 2023-12-01 | 0.6667 | 4 | 6 | 123,868 | 111,937 |
| 2023-06-01 | 0.7436 | 29 | 39 | 583,200 | 126,821 |
| 2022-06-01 | 0.9167 | 44 | 48 | 827,110 | 334,126 |
| 2022-03-01 | 0.6512 | 28 | 43 | 157,922 | 248,193 |
| 2021-12-01 | 0.1765 | 3 | 17 | 32,500 | 158,075 |
| 2021-09-01 | 0.75 | 6 | 8 | 32,500 | 57,058 |
| 2021-06-01 | 1.3448 | 39 | 29 | 433,909 | 175,751 |
| 2021-03-01 | 0.2222 | 6 | 27 | 46,520 | 387,484 |
| 2020-12-01 | 0.25 | 5 | 20 | 100,000 | 445,000 |
| 2020-09-01 | 0.3846 | 15 | 39 | 164,404 | 599,326 |
| 2020-06-01 | 1.5556 | 42 | 27 | 1,160,846 | 186,637 |
| 2020-03-01 | 0.8 | 12 | 15 | 92,828 | 109,200 |
| 2019-12-01 | 0.5769 | 15 | 26 | 97,448 | 209,674 |
| 2019-09-01 | 0.5 | 5 | 10 | 246,768 | 72,180 |
| 2019-06-01 | 2.0 | 36 | 18 | 556,007 | 87,312 |
| 2018-12-01 | 0.4211 | 8 | 19 | 66,500 | 223,738 |
| 2018-09-01 | 0.2 | 5 | 25 | 36,091 | 272,866 |
| 2018-06-01 | 1.9333 | 29 | 15 | 489,700 | 114,466 |
| 2018-03-01 | 0.5 | 2 | 4 | 88,885 | 57,770 |
| 2017-12-01 | 0.4167 | 5 | 12 | 68,770 | 196,730 |
| 2017-09-01 | 0.6 | 3 | 5 | 43,985 | 77,275 |
| 2017-06-01 | 1.56 | 39 | 25 | 509,182 | 209,144 |
| 2017-03-01 | 0.4286 | 3 | 7 | 35,000 | 70,000 |
| 2016-12-01 | 1.8333 | 11 | 6 | 233,000 | 100,000 |
| 2016-09-01 | 0.6 | 3 | 5 | 40,000 | 80,000 |
| 2016-06-01 | 3.0 | 30 | 10 | 412,491 | 54,574 |
| 2016-03-01 | 1.0 | 7 | 7 | 21,800 | 36,000 |
| 2015-12-01 | 0.5 | 3 | 6 | 58,000 | 36,000 |
| 2015-09-01 | 1.25 | 5 | 4 | 138,000 | 36,000 |
| 2015-06-01 | 5.5 | 22 | 4 | 109,250 | 55,000 |
| 2015-03-01 | 0.4 | 8 | 20 | 64,849 | 119,349 |
| 2014-12-01 | 0.3333 | 7 | 21 | 37,225 | 138,041 |
| 2014-09-01 | 0.4 | 14 | 35 | 583,500 | 894,007 |
| 2014-06-01 | 0.625 | 20 | 32 | 467,000 | 501,900 |
| 2014-03-01 | 1.0 | 4 | 4 | 16,725 | 26,887 |
| 2013-12-01 | 0.6 | 9 | 15 | 97,997 | 195,000 |
| 2013-09-01 | 0.3636 | 12 | 33 | 216,987 | 729,193 |
| 2013-06-01 | 0.375 | 24 | 64 | 263,853 | 1,733,974 |
| 2013-03-01 | 0.4167 | 25 | 60 | 630,143 | 8,742,900 |
| 2012-03-01 | 0.4063 | 13 | 32 | 8,237,883 | 7,122,644 |
| 2011-12-01 | 3.5 | 7 | 2 | 2,017,690 | 97,441 |
| 2011-06-01 | 3.0 | 6 | 2 | 71,384 | 0.00 |
| 2011-03-01 | 1.64 | 82 | 50 | 27,986,922 | 21,650,746 |
Pacira Pharmaceuticals Notable Stakeholders
A Pacira Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Pacira Pharmaceuticals often face trade-offs trying to please all of them. Pacira Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Pacira Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Frank Lee | CEO Director | Profile | |
| David Stack | Chairman and CEO | Profile | |
| James Jones | Senior Vice President Chief Medical Officer | Profile | |
| Scott Braunstein | Senior Vice President - Strategy and Corporate Development | Profile | |
| James Scibetta | Pres and CFO | Profile | |
| Charles Reinhart | CFO | Profile | |
| Scott MD | Sr. VP of Strategy and Corporate Devel. | Profile | |
| Gary Pace | Independent Director | Profile | |
| Mark Kronenfeld | Independent Director | Profile | |
| John Longenecker | Independent Director | Profile | |
| Mark Froimson | Director | Profile | |
| Laura Brege | Independent Director | Profile | |
| Yvonne Greenstreet | Independent Director | Profile | |
| Dennis Winger | Independent Director | Profile | |
| Paul Hastings | Independent Director | Profile | |
| Andreas Wicki | Independent Director | Profile | |
| Daryl Gaugler | Chief Officer | Profile | |
| Charles Laranjeira | Chief Technical Officer | Profile | |
| Dennis McLoughlin | Chief Commercial Officer | Profile | |
| Richard Scranton | Chief Scientific Officer | Profile | |
| Susan Mesco | IR Contact Officer | Profile | |
| Roy Winston | Chief Clinical Officer | Profile | |
| Jonathan MD | Chief Officer | Profile | |
| Lauren Riker | Principal Finance | Profile | |
| Richard Kahr | Vice Resources | Profile | |
| Robert Weiland | Chief Commercial Officer | Profile | |
| DO Ellis | Chief Officer | Profile | |
| III CPA | Chief Officer | Profile | |
| Max Reinhardt | Pres World | Profile | |
| Kristen JD | Chief Secretary | Profile | |
| Kristen Williams | Chief Administrative Officer, General Counsel, Secretary | Profile | |
| Roy MD | Chief Officer | Profile | |
| Esq III | Chief Officer | Profile |
About Pacira Pharmaceuticals Management Performance
The success or failure of an entity such as Pacira Pharmaceuticals often depends on how effective the management is. Pacira Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Pacira management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Pacira management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.05 | 0.05 | |
| Return On Capital Employed | 0.06 | 0.06 | |
| Return On Assets | 0.03 | 0.03 | |
| Return On Equity | 0.05 | 0.05 |
The data published in Pacira Pharmaceuticals' official financial statements usually reflect Pacira Pharmaceuticals' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Pacira Pharmaceuticals. For example, before you start analyzing numbers published by Pacira accountants, it's critical to develop an understanding of what Pacira Pharmaceuticals' liquidity, profitability, and earnings quality are in the context of the Pharmaceuticals space in which it operates.
Please note, the presentation of Pacira Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Pacira Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Pacira Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Pacira Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Pacira Pharmaceuticals' management manipulating its earnings.
Pacira Pharmaceuticals Workforce Analysis
Traditionally, organizations such as Pacira Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Pacira Pharmaceuticals within its industry.Pacira Pharmaceuticals Manpower Efficiency
Return on Pacira Pharmaceuticals Manpower
| Revenue Per Employee | 949.3K | |
| Revenue Per Executive | 20.5M | |
| Net Income Per Employee | 59K | |
| Net Income Per Executive | 1.3M | |
| Working Capital Per Employee | 580.3K | |
| Working Capital Per Executive | 12.5M |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pacira Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Pacira Stock please use our How to Invest in Pacira Pharmaceuticals guide.You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Complementary Tools for Pacira Stock analysis
When running Pacira Pharmaceuticals' price analysis, check to measure Pacira Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pacira Pharmaceuticals is operating at the current time. Most of Pacira Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Pacira Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pacira Pharmaceuticals' price. Additionally, you may evaluate how the addition of Pacira Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal |
Is Pacira Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pacira Pharmaceuticals. If investors know Pacira will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pacira Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.291 | Earnings Share 0.89 | Revenue Per Share 14.603 | Quarterly Revenue Growth 0.054 | Return On Assets 0.0335 |
The market value of Pacira Pharmaceuticals is measured differently than its book value, which is the value of Pacira that is recorded on the company's balance sheet. Investors also form their own opinion of Pacira Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Pacira Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pacira Pharmaceuticals' market value can be influenced by many factors that don't directly affect Pacira Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pacira Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Pacira Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pacira Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.